Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s sentinel physician surveillance network, January 2015

Eurosurveillance

Volumn 20, Issue 4, 2015, Pages

  Skowronski, D M ^a,b   Chambers, C ^a   Sabaiduc, S ^a   De Serres, G ^c,d,e   Dickinson, J A ^f   Winter, A L ^g   Drews, S J ^h,i   Fonseca, K ^f,j   Charest, H ^c   Gubbay, J B ^g,k   Petric, M ^b   Krajden, M ^a,b   Kwindt, T L ^a,b   Martineau, C ^c   Eshaghi, A ^g   Bastien, N ^l   Li, Y ^l,m  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c National Institute of Health of Quebec   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g PUBLIC HEALTH ONTARIO   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ Prov Laboratory of Northern Alberta   (Canada)

^j Alberta Provincial Laboratory   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^m UNIVERSITY OF MANITOBA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; INFLUENZA VACCINE; VIRUS ANTIGEN;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANADA; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLYCOSYLATION; HEALTH CARE SURVEY; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INFLUENZA A (H3N2); MALE; MORBIDITY; MORTALITY; MUTATION; NONHUMAN; PHYLOGENY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SENTINEL SURVEILLANCE; ADOLESCENT; CHILD; DNA SEQUENCE; GENERAL PRACTITIONER; GENETICS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; MOLECULAR GENETICS; NASOPHARYNX; NOSE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; VACCINATION; VERY ELDERLY; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, VIRAL; CANADA; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NASOPHARYNX; NOSE; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIANS, FAMILY; POLYMERASE CHAIN REACTION; SENTINEL SURVEILLANCE; SEQUENCE ANALYSIS, DNA; VACCINATION;

EID: 84922804504     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2015.20.4.21022     Document Type: Article

References (36)

1. Public Health Agency of Canada (PHAC). Flu Watch. Weekly reports 2014-2015 season. January 11 to January 17, 2015 (week 2). Ottawa: PHAC. [Accessed: 25 Jan 2015]. Available from: http://www.phac-aspc.gc.ca/fluwatch/14-15/w02_15/index-eng.php
2. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, et al. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014. Euro Surveill. 2014;19(5):20690. http://dx.doi.org/10.2807/1560-7917.ES2014.19.5.20690 PMID:24524234
3. Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter AL, Mahmud SM, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada’s sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5):20394. PMID:23399422
4. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE. 2014;9(3):e92153. http://dx.doi.org/10.1371/journal.pone.0092153 PMID:24667168
5. BC Centre for Disease Control (BCCDC). Influenza surveillance reports: BC influenza surveillance bulletin: Influenza season 2014-15. Report no. 14. Week 2. January 11 to January 17, 2015. Vancouver, BCCDC. [Accessed: 25 Jan 2015]. Available from: http://www.bccdc.ca/NR/rdonlyres/27E73D7B-55D4-47C0-B2EB-68B94D2618DD/0/InfluBulletin_Number14_ Week2_201415.pdf
6. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014;210(1):126-37. http://dx.doi.org/10.1093/infdis/jiu048 PMID:24446529
7. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis. 2012;55(3):332-42. http://dx.doi.org/10.1093/cid/cis431 PMID:22539661
8. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO. [Accessed: 19 Jan 2015]. Available from: http://www.who.int/ influenza/vaccines/virus/recommendations/en/index.html
9. Bush RM, Bender CA, Subbarao K, Cox NJ, Fitch WM. Predicting the evolution of human influenza A. Science. 1999;286(5446):1921-5. http://dx.doi.org/10.1126/science.286.5446.1921 PMID:10583948
10. Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5(3):e9490. http://dx.doi.org/10.1371/journal. pone.0009490PMID:20224823
11. Rambaut A. FigTree v1.4.0, a graphical viewer of phylogenetic trees. Edinburgh: University of Edinburgh. Accessed 19 Jan 2015. Available from: http://tree.bio.ed.ac.uk/software/figtree
12. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation. Summary Europe, November 2014. Surveillance report. Stockholm: ECDC. 2014. Available from: http://www.ecdc.europa.eu/en/publications/Publications/ERLI-Net%20report%20November%202014.pdf
13. Cox NJ, Bender CA. The molecular epidemiology of influenza viruses. Semin Virol. 1995;6(6):359-70. http://dx.doi. org/10.1016/S1044-5773(05)80013-7
14. Ndifon W, Wingreen NS, Levin SA. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci USA. 2009;106(21):8701-6. http://dx.doi.org/10.1073/ pnas.0903427106PMID:19439657
15. Popova L, Smith K, West AH, Wilson PC, James JA, Thompson LF, et al. Immunodominance of antigenic site B over site A of hemagglutinin of recent H3N2 influenza viruses. PLoS ONE. 2012;7(7):e41895. http://dx.doi.org/10.1371/journal.pone.0041895 PMID:22848649
16. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science. 2013;342(6161):976-9. http://dx.doi.org/10.1126/science.1244730PMID:24264991
17. Tate MD, Job ER, Deng Y-M, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294-316. http://dx.doi.org/10.3390/v6031294PMID:24638204
18. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669-83. http://dx.doi.org/10.1586/ eri.11.51PMID:21692672
19. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol. 2010;84(13):6769-81. http://dx.doi.org/10.1128/JVI.00458-10 PMID:20410266
20. Centers for Disease Control and Prevention (CDC). FluView. 2014-2015 influenza season week 2 ending January 17, 2015. U.S. Virologic Surveillance, Influenza Virus Characterization. Atlanta: CDC. [Accessed: 25 Jan 2015]. Available from: http://www.cdc.gov/flu/weekly
21. Public Health Agency of Canada (PHAC). Vaccine coverage amongst adult Canadians: Results from the 2012 adult National Immunization Coverage (aNIC) survey. Ottawa: PHAC. [Accessed: 19 Jan 2015]. Available from: http://www.phac-aspc.gc.ca/im/nics-enva/vcac-cvac-eng.php
22. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015;64(1):10-5. PMID:25590680
23. Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J. 2006;25(10):870-9. http://dx.doi.org/10.1097/01.inf.0000237829.66310.85 PMID:17006279
24. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25(10):860-9. http://dx.doi.org/10.1097/01.inf.0000237797.14283.cf PMID:17006278
25. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685-96. http://dx.doi.org/10.1056/NEJMoa065368PMID:17301299
26. Advisory Committee on Immunization Practices (ACIP). Grading of recommendations, assessment, development, and evaluation (GRADE) for use of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children. Atlanta: Centers for Disease Control and Prevention. [Accessed: 25 Jan 2015]. Available from: http://www.cdc.gov/vaccines/acip/recs/GRADE/LAIV-child.html
27. Public Health Agency of Canada. Revised wording to the National Advisory Committee on Immunization (NACI) recommendation for live attenuated influenza vaccine (LAIV) in healthy children and adolescents 2-17 years of age. Canada Commun Dis Rep. 2013;39(4). [Accessed: 25 Jan 2015]. Available from: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/13vol39/acs-dcc-4/rev-eng.php
28. Centers for Disease Control and Prevention (CDC). CDC statement on LAIV effectiveness and vaccination of children. Atlanta: CDC. [Accessed: 25 Jan 2015]. Available from: http:// www.cdc.gov/flu/news/nasal-spray-effectiveness.htm
29. Castilla J, Martinez-Baz I, Nacascues A, Fernandez-Alonso M, Reina G, Guevara M, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in Navarre, Spain: 2013/14 mid-season analysis. Euro Surveill. 2014;19(6):pii=20700.
30. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013;56(10):1363-9. http://dx.doi.org/10.1093/cid/cit060 PMID:23413420
31. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-13 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis. 2014;jiu650. PMID:25416812
32. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2014;58(3):319-27. http://dx.doi.org/10.1093/cid/cit736PMID:24235265
33. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59(10):1375-85. http://dx.doi.org/10.1093/cid/ciu680 PMID:25270645
34. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci USA. 1999;96(24):14001-6. http://dx.doi.org/10.1073/pnas.96.24.14001PMID:10570188
35. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol. 2007;36(3):623-31. http://dx.doi.org/10.1093/ije/dym021 PMID:17403908
36. De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled trials. Euro Surveill. 2013;18(37):20585. PMID:24079398